WHO Drug Information Vol. 17, No. 4, 2003
(2003; 58 pages) Ver el documento en el formato PDF
Índice de contenido
Abrir esta carpeta y ver su contenidoRegulatory Challenges
Abrir esta carpeta y ver su contenidoSafety and Efficacy Issues
Abrir esta carpeta y ver su contenidoAspects of Quality Assurance
Cerrar esta carpetaRegulatory and Safety Action
Ver el documentoRecommended influenza vaccine for 2004 (Southern hemisphere)
Ver el documentoDaclizumab: safety alert
Ver el documentoNefazodone discontinued
Ver el documentoLevomethadyl discontinued
Ver el documentoDaptomycin: new class of antibiotic approved
Ver el documentoTetrahydrogestrinone: grave risks to health
Ver el documentoCoronary stents and thrombosis
Ver el documentoBicalutamide: do not use in localized prostate cancer
Ver el documentoRecombinant antihaemophilic factor: dose monitoring required
Ver el documentoNimesulide-containing products re-evaluated
Ver el documentoMemantine approved for Alzheimer disease
Ver el documentoVirologic non-response in more HIV combinations
Abrir esta carpeta y ver su contenidoPersonal Perspectives
Abrir esta carpeta y ver su contenidoCurrent Topics
Abrir esta carpeta y ver su contenidoEssential Medicines
Ver el documentoRecommended International Nonproprietary Names: List 50
Ver el documentoSelected WHO Publications of Related Interest
 

Recommended influenza vaccine for 2004 (Southern hemisphere)

World Health Organization - National Authorities are responsible for recommendations regarding the use of influenza vaccine and should approve the specific vaccine viruses used in each country.

It is recommended that influenza virus vaccines to be used in the 2004 season (Southern hemisphere winter) contain the following:

• an A/New Caledonia/20/99 (H1N1)-like virus;

• an A/Fujian/411/2002 (H3N2)-like virus {A/Kumamoto/102/2002 and A/Wyoming/3/2003 an egg-grown A/Fujian/411/2002 (H3N2)-like virus}

• a B/Hong Kong/330/2001-like virus {Currently used vaccine viruses include B/Shandong/7/97, B/Hong Kong/330/200, B/Hong Kong/1434/2002. B/Brisbane/32/2002 is also available as a vaccine virus.}


Information concerning reagents for use in laboratory standardization of inactivated vaccine and reference strains for antigenic analysis is available on http://www.who.int/influenza.

Reference: Weekly Epidemiological Record, No. 43. 24 October 2003.

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013